Literature DB >> 33411010

Risk factors for imminent fractures: a substudy of the FRISBEE cohort.

L Iconaru1, M Moreau2, F Baleanu3, V Kinnard4, A Charles5, A Mugisha4, M Surquin4, F Benoit4, R Karmali3, M Paesmans2, J J Body3,5, P Bergmann5,6.   

Abstract

Multiple factors increase the risk of an imminent fracture, including a recent fracture, older age, osteoporosis, comorbidities, and the fracture site. These findings could be a first step in the development of a model to predict an imminent fracture and select patients most at need of immediate treatment.
INTRODUCTION: The risk of a recurrent fragility fracture is maximal during the first 2 years following an incident fracture. In this prospective cohort study, we looked at the incidence of recurrent fractures within 2 years after a first incident fracture and we assessed independent clinical risk factors (CRFs) increasing this imminent fracture risk.
METHODS: A total of 3560 postmenopausal women recruited from 2007 to 2013 were surveyed yearly for the occurrence of fragility fractures. We identified patients who sustained a fracture during the first 2 years following a first incident fragility fracture. We quantified the risk of a new fracture and assessed independent CRFs, associated with an imminent fracture at various sites.
RESULTS: A recent fracture was a significant CRF for an imminent fracture (OR (95% CI): 3.7 (2.4-5.7) [p < 0.0001]). The incidence of an imminent fracture was higher in subjects above 80 years (p < 0.001). Other CRFs highly predictive in a multivariate analysis were osteoporosis diagnosis (p < 0.01), a central fracture as the index fracture (p < 0.01), and the presence of comorbidities (p < 0.05), with likelihood ratios of 1.9, 1.9, and 2.2, respectively. An imminent fracture was better predicted by a central fracture (p < 0.01) than by a major osteoporotic fracture. The hazard ratio was the highest for a central fracture.
CONCLUSION: In patients with a recent fracture, older age, osteoporosis, comorbidities, and fracture site were associated with an imminent fracture risk. These findings could be a first step in the development of a model to predict an imminent fracture and select patients most at need of immediate and most appropriate treatment.

Entities:  

Keywords:  Clinical risk factors; Imminent fracture

Mesh:

Year:  2021        PMID: 33411010     DOI: 10.1007/s00198-020-05772-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  37 in total

1.  Characteristics of recurrent fractures.

Authors:  J A Kanis; H Johansson; A Odén; N C Harvey; V Gudnason; K M Sanders; G Sigurdsson; K Siggeirsdottir; L A Fitzpatrick; F Borgström; E V McCloskey
Journal:  Osteoporos Int       Date:  2018-06-12       Impact factor: 4.507

2.  Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.

Authors:  Eugene V McCloskey; Helena Johansson; Anders Oden; Matt Austin; Ethel Siris; Andrea Wang; E Michael Lewiecki; Roman Lorenc; Cesar Libanati; John A Kanis
Journal:  J Bone Miner Res       Date:  2012-07       Impact factor: 6.741

3.  Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.

Authors:  David L Kendler; Fernando Marin; Cristiano A F Zerbini; Luis A Russo; Susan L Greenspan; Vit Zikan; Alicia Bagur; Jorge Malouf-Sierra; Péter Lakatos; Astrid Fahrleitner-Pammer; Eric Lespessailles; Salvatore Minisola; Jean Jacques Body; Piet Geusens; Rüdiger Möricke; Pedro López-Romero
Journal:  Lancet       Date:  2017-11-09       Impact factor: 79.321

Review 4.  A decade of FRAX: how has it changed the management of osteoporosis?

Authors:  John A Kanis; Nicholas C Harvey; Helena Johansson; Enwu Liu; Liesbeth Vandenput; Mattias Lorentzon; William D Leslie; Eugene V McCloskey
Journal:  Aging Clin Exp Res       Date:  2020-02-11       Impact factor: 3.636

5.  Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.

Authors:  Richard Eastell; Clifford J Rosen; Dennis M Black; Angela M Cheung; M Hassan Murad; Dolores Shoback
Journal:  J Clin Endocrinol Metab       Date:  2019-05-01       Impact factor: 5.958

Review 6.  Imminent fracture risk.

Authors:  C Roux; K Briot
Journal:  Osteoporos Int       Date:  2017-02-24       Impact factor: 4.507

7.  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.

Authors:  Kenneth G Saag; Jeffrey Petersen; Maria Luisa Brandi; Andrew C Karaplis; Mattias Lorentzon; Thierry Thomas; Judy Maddox; Michelle Fan; Paul D Meisner; Andreas Grauer
Journal:  N Engl J Med       Date:  2017-09-11       Impact factor: 91.245

8.  The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).

Authors:  Dennis M Black; Ian R Reid; Jane A Cauley; Felicia Cosman; Ping Chung Leung; Peter Lakatos; Kurt Lippuner; Steven R Cummings; Trisha F Hue; Amitava Mukhopadhyay; Monique Tan; R Paul Aftring; Richard Eastell
Journal:  J Bone Miner Res       Date:  2015-05       Impact factor: 6.741

9.  Risk of imminent fracture following a previous fracture in a Swedish database study.

Authors:  J Banefelt; K E Åkesson; A Spångéus; O Ljunggren; L Karlsson; O Ström; G Ortsäter; C Libanati; E Toth
Journal:  Osteoporos Int       Date:  2019-01-24       Impact factor: 4.507

10.  Study on Zoledronic Acid Reducing Acute Bone Loss and Fracture Rates in Elderly Postoperative Patients with Intertrochanteric Fractures.

Authors:  Zhong Liu; Chun-Wen Li; Yi-Fan Mao; Kang Liu; Bo-Cheng Liang; Lian-Guo Wu; Xiao-Lin Shi
Journal:  Orthop Surg       Date:  2019-05-06       Impact factor: 2.071

View more
  2 in total

1.  Determination of E-modulus of cancellous bone derived from human humeri and validation of plotted single trabeculae: Development of a standardized humerus bone model.

Authors:  Florian Kuhn; Rasmus Johannes Clausing; Alexander Stiller; Carlos Alfonso Fonseca Ulloa; Christian Foelsch; Markus Rickert; Alexander Jahnke
Journal:  J Orthop       Date:  2022-07-11

2.  Fragility Fractures in Postmenopausal Women: Development of 5-Year Prediction Models Using the FRISBEE Study.

Authors:  Felicia Baleanu; Michel Moreau; Alexia Charles; Laura Iconaru; Rafik Karmali; Murielle Surquin; Florence Benoit; Aude Mugisha; Marianne Paesmans; Michel Rubinstein; Serge Rozenberg; Pierre Bergmann; Jean-Jacques Body
Journal:  J Clin Endocrinol Metab       Date:  2022-05-17       Impact factor: 6.134

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.